VBLT Stock Overview
Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vascular Biogenics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.16 |
| 52 Week High | US$0.32 |
| 52 Week Low | US$0.10 |
| Beta | 0.71 |
| 1 Month Change | -33.33% |
| 3 Month Change | -45.07% |
| 1 Year Change | 9.17% |
| 3 Year Change | -86.55% |
| 5 Year Change | -88.53% |
| Change since IPO | -97.33% |
Recent News & Updates
Recent updates
VBL Therapeutics receives non-compliance letter from Nasdaq
Sep 01VBL Therapeutics GAAP EPS of -$0.12
Aug 15VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals
Jul 19Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation
May 18
Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump
Sep 03How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?
Mar 17How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?
Jan 28VBL Therapeutics expands the ovarian cancer trial in Europe
Dec 29Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?
Dec 24
Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 19VBL Therapeutics EPS beats by $0.01, misses on revenue
Nov 16Shareholder Returns
| VBLT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -34.5% | -2.5% | -3.2% |
| 1Y | 9.2% | -3.7% | 19.3% |
Return vs Industry: VBLT exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: VBLT underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| VBLT volatility | |
|---|---|
| VBLT Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VBLT's share price has been volatile over the past 3 months.
Volatility Over Time: VBLT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 7 | Dror Harats | www.vblrx.com |
Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd.
Vascular Biogenics Ltd. Fundamentals Summary
| VBLT fundamental statistics | |
|---|---|
| Market cap | US$12.11m |
| Earnings (TTM) | -US$15.95m |
| Revenue (TTM) | US$481.00k |
25.2x
P/S Ratio-0.8x
P/E RatioIs VBLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VBLT income statement (TTM) | |
|---|---|
| Revenue | US$481.00k |
| Cost of Revenue | US$17.00k |
| Gross Profit | US$464.00k |
| Other Expenses | US$16.42m |
| Earnings | -US$15.95m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 96.47% |
| Net Profit Margin | -3,317.05% |
| Debt/Equity Ratio | 0% |
How did VBLT perform over the long term?
See historical performance and comparison